Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis

This publication has 32 references indexed in Scilit:

• Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis
  International Journal of Colorectal Disease, 2011
• Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status.
  Journal of Clinical Oncology, 2010
• American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
  Journal of Clinical Oncology, 2009
• Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
  The Lancet Oncology, 2008
• EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
  Journal of Clinical Oncology, 2008
• Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK
  Annals of Oncology, 2008
• Practical methods for incorporating summary time-to-event data into meta-analysis
  Trials, 2007
• Aggregate data meta‐analysis with time‐to‐event outcomes
  Statistics in Medicine, 2002
• Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial
  The Lancet, 2002
• Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints
  Statistics in Medicine, 1998